[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585746":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":72,"collaborators":10,"id":74,"slug":10,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":10,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":10,"maxAge":10,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":10,"overallStatus":90,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"ARCE Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non Interventional",null,"All subjects with AML or MDS who are enrolled in a parent study and were exposed to ARD103 CAR-T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study.",[13],"Other: Non interventional study",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","Non interventional study","Non Intervention, an observation LTFU study",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"ARCE Therapeutics, Inc ARCE","CONTACT","+886-2-26581868","contact@arcetherapeutics.com",[27,44,57],{"facility":28,"status":10,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Novant Health Cancer Institute","Charlotte","North Carolina","28204","United States",{"type":34,"coordinates":35},"Point",[36,37],-80.84313,35.22709,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":42,"phoneExt":10,"email":43},"Kunal Shah","980-302-6297","kashah@novanthealth.org",{"facility":28,"status":10,"city":45,"state":30,"zip":46,"country":32,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Winston-Salem","27201",{"type":34,"coordinates":48},[49,50],-80.24422,36.09986,{"lat":50,"lon":49},[53],{"name":54,"role":23,"phone":55,"phoneExt":10,"email":56},"Gait Jordan","336-718-8553","PJordan@novanthealth.org",{"facility":58,"status":10,"city":59,"state":60,"zip":61,"country":32,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":34,"coordinates":63},[64,65],-95.36327,29.76328,{"lat":65,"lon":64},[68],{"name":69,"role":23,"phone":70,"phoneExt":10,"email":71},"Dr. Abhishek Maiti","713-745-3228","AMaiti@mdanderson.org",{"type":73,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100585746",false,"NCT06906380","A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1\u002F2 Study and Treated With ARD103 CAR-T Cell Therapies","Inclusion Criteria:\n\n* The participant has R\u002FR AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.\n* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study","ALL",{"count":82,"type":83},49,"ESTIMATED","OBSERVATIONAL","This study will evaluate the long-term safety of ARD103 cellular therapies",[87,88,89],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, in Relapsed or Refractory","MDS (Myelodysplastic Syndrome)","NOT_YET_RECRUITING","2025-12-04",{"date":93,"type":94},"2025-12-08","ACTUAL",{"date":96,"type":83},"2026-03-15",{"date":98,"type":83},"2040-10-31",{"name":5,"class":6},3]